<- Go Home
iBio, Inc.
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States.
Market Cap
$20.8M
Volume
965.8K
Cash and Equivalents
$5.3M
EBITDA
-$17.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$50.0K
Profit Margin
100.00%
52 Week High
$17.60
52 Week Low
$1.02
Dividend
N/A
Price / Book Value
0.83
Price / Earnings
-0.27
Price / Tangible Book Value
1.05
Enterprise Value
$33.4M
Enterprise Value / EBITDA
-2.00
Operating Income
-$18.2M
Return on Equity
-81.08%
Return on Assets
-24.05
Cash and Short Term Investments
$5.3M
Debt
$18.0M
Equity
$24.9M
Revenue
$50.0K
Unlevered FCF
-$16.7M
Sector
Biotechnology
Category
N/A